Edward M. Kaye, MD
Edward M. Kaye, M.D. Chief Executive Officer and Director of Stoke Therapeutics How did you become interested in the field? My interest in genetic medicine began as a biochemical geneticist and pediatric neurologist. Back in the 1990s, when I was treating patients, I saw first-hand ...
Interview with Roberto El-Khoury, PhD
Roberto El-Khoury, PhD Eli Lilly and Company How did you become interested in the field? I recall being drawn to the field of oligonucleotide therapeutics in high school biology classes, but it was only years later, when I was offered the opportunity to pursue my ...
Interview with Leonora Abdullahu, PhD
Leonora Abdullahu, PhD Genetic Medicines Search and Evaluation Eli Lilly & Company How did you become interested in the field?In September 2016, I joined Prof. Masad Damha’s lab at McGill University as a graduate student. To my luck, the Annual OTS meeting was being held ...
Interview with Sudhir Agrawal, D.Phil.
Sudhir Agrawal, D.Phil. Founder and President, Arnay Sciences Affiliate Professor in the Department of Medicine, UMass Chan Medical School How did you become interested in the field? It was a call from Paul Zamecnik in mid-1986. At the time, I was doing my ...
Interview with Steven F. Dowdy, PhD
Steven F. Dowdy, Ph.D.ProfessorDepartment of Cellular & Molecular Medicine,University of California San Diego (UCSD), School of Medicine How did you become interested in the field of oligonucleotides? I started my lab in 1994 as an Investigator of the Howard Hughes Medical Institute (HHMI) and an ...
Interview with Shipra Malik, PhD
Shipra Malik, PhDRaman Bahal LabDepartment of Pharmaceutical SciencesUniversity of Connecticut How did you become interested in the field of oligonucleotides? Being from pharmaceutics background, my master’s research was focused on designing nano-formulations to improve the local delivery of small molecules. As I was looking for ...
Interview with Saul Martinez Montero, PhD
Saul Martinez Montero, PhD, Executive Director, Head of Chemistry BaseCure Therapeutics How did you become interested in the field of oligonucleotides? My graduate studies focused on nucleoside synthesis and on the applications of nucleosides as antiviral agents. In 2012, towards the end of my PhD, ...
Interview with Pawan Kumar, PhD
Pawan Kumar, PhD Principal Scientist, Takeda Pharmaceuticals How did you become interested in the field of oligonucleotides? I was first exposed to the field of therapeutic oligonucleotides as an exchange PhD student in the Hrdlicka’s lab at the University of Idaho, where I developed ...
Interview with M.Sc. Philipp Niklas Ostermann, PhD Student
M.Sc. Philipp Niklas Ostermann PhD Student Heiner Schaal Lab Institute of Virology University Hospital DĂ¼sseldorf How did you become interested in the field of oligonucleotides? I first encountered the use of antisense oligonucleotides as potential therapeutics during my master’s thesis, which was about inhibition of ...
Interview with Hermona Soreq, PhD
Hermona Soreq, PhDThe Slesinger Professor of Molecular Neuroscience at The Hebrew University of Jerusalem’s Edmond and Lily Safra Center for Brain Sciences (ELSC) and the Silberman Institute of Life Sciences How did you become interested in the field of oligonucleotides? During my PhD studies ...